Hormona, a London-based femtech startup, has secured $6.6 million in Seed funding to transform how women manage their hormone health. The round was led by Voima Ventures in Helsinki and co-led by SuperNode Global in London. Additional investors included DLF Ventures, Nascent Invest, and Techstars.
Hormonal issues often go undiagnosed for years. Many women suffer from symptoms like fatigue, mood changes, and sleep problems without getting clear answers. Hormona wants to fix this with easy, lab-free testing and smart, AI-driven insights.
Co-founder and CEO Karolina Löfqvist built Hormona from personal frustration. She spent years struggling with symptoms that doctors dismissed. Only later did she discover a common hormonal condition had been missed all along. That experience sparked the idea for a platform that gives women real-time hormone tracking and clear data from the start—without blood draws or guesswork.
A New Era of Hormone Testing
Hormona’s at-home tests are fully quantitative and deliver over 90% accuracy compared to lab samples. But unlike traditional panels that cost up to $175, Hormona offers affordable, ongoing monitoring through a monthly subscription.
The company’s mobile app is gaining traction fast. It’s now downloaded in over 190 countries, with a 30% month-over-month growth rate. Even more impressive—80% of users remain active a year after signing up. That’s rare in health tech and shows how much women need better tools.
Hormona’s social media success mirrors this demand. With more than 100 million views on Instagram and over 5 million TikTok likes, the platform is building a strong community. Users aren’t just curious—they’re engaged.
Fueling Growth and Personalization
With its new funding, Hormona plans to launch more hormone tests and expand its B2B offerings. The team will also grow its infrastructure, improve customer support, and add new features to its Hormona+ subscription. This includes symptom plans, nutrition tips tailored to cycle phases, and alerts for partners to offer better support.
Hormona’s board remains all-female. New members include Voima Ventures’ Inka Mero and SuperNode’s Gina King. Both bring deep experience in science-led startups and women-focused leadership.
King believes Hormona is building what women have lacked for too long—tools that replace guesswork with clarity. “The future of women’s health is proactive, data-driven, and deeply personalized,” she said. “Hormona is making that future real.”
The startup has now raised a total of $8.6 million and built a 12-person team. At a time when women’s health remains underfunded—receiving just 2% of global medical research spending—Hormona’s raise is a step toward closing the gender gap.
As Löfqvist put it, “We’re done with the waiting, guessing, and suffering. It’s time for women to take back control of their hormone health.”
